Till startsida
Sitemap
To content Read more about how we use cookies on gu.se

Jan Lycke

Professor, adjungerad

Jan Lycke
Professor, adjungerad
jan.lycke@gu.se
+46 31-342 9047
0733-109149

Postal Address: Gröna stråket 11, plan 3, 41345 Göteborg
Visiting Address: Neurosjukvården, Gröna stråket 11, plan 3, SU/Sahlgrenska sjukhuset , 41345 Göteborg


Department of Clinical Neuroscience at Institute of Neuroscience and Physiology (More Information)
Box 430
405 30 Göteborg
Visiting Address: Blå stråket 7, plan 3, Sahlgrenska , 413 45 Göteborg

Latest publications

Inflammation-related plasma and CSF biomarkers for sclerosis
J. Huang, M. Khademi, L. Fugger, O. Lindhe, Lenka Novakova et al.
Proceedings of the National Academy of Sciences of the United States of America, Journal article 2020
Journal article

Blood neurofilament light levels segregate treatment effects in multiple sclerosis
Bénédicte Delcoigne, Ali Manouchehrinia, Christian Barro, Pascal Benkert, Zuzanna Michalak et al.
Neurology, Journal article 2020
Journal article

Cancer Risk for Fingolimod, Natalizumab, and Rituximab in Multiple Sclerosis Patients
Peter Alping, Johan Askling, Joachim Burman, Katharina Fink, Anna Fogdell-Hahn et al.
Annals of Neurology, Journal article 2020
Journal article

Timing of high-efficacy therapy for multiple sclerosis: a retrospective observational cohort study.
Anna He, Bernd Merkel, James William L Brown, Lana Zhovits Ryerson, Ilya Kister et al.
The Lancet. Neurology, Journal article 2020
Journal article

Infection Risks among Patients with Multiple Sclerosis Treated with Fingolimod, Natalizumab, Rituximab, and Injectable Therapies
G. Luna, P. Alping, J. Burman, K. Fink, A. Fogdell-Hahn et al.
JAMA Neurology, Journal article 2020
Journal article

Comparative effectiveness of dimethyl fumarate as the initial and secondary treatment for MS
Mathias Granqvist, Joachim Burman, Martin Gunnarsson, Jan Lycke, Petra Nilsson et al.
Multiple Sclerosis Journal, Journal article 2019
Journal article

Cerebrospinal fluid growth-associated protein 43 in multiple sclerosis.
Åsa P Sandelius, Sofia Sandgren, Markus Axelsson, Clas Malmeström, Lenka Novakova et al.
Scientific reports, Journal article 2019
Journal article

Diagnostic Value of Cerebrospinal Fluid Neurofilament Light Protein in Neurology: A Systematic Review and Meta-analysis.
Claire Bridel, Wessel N van Wieringen, Henrik Zetterberg, Betty M Tijms, Charlotte E Teunissen et al.
JAMA neurology, Journal article 2019
Journal article

Showing 11 - 20 of 79

2019

Efficacy of alemtuzumab over 6 years in relapsing-remitting multiple sclerosis patients who relapsed between courses 1 and 2: Post hoc analysis of the CARE-MS studies
B. Van Wijmeersch, B. A. Singer, A. Boster, S. Broadley, O. Fernandez et al.
Multiple Sclerosis Journal, Journal article 2019
Journal article

Natalizumab, rituximab and fingolimod as escalation therapy in multiple sclerosis
M. Boremalm, A. Juto, Markus Axelsson, Lenka Novakova, T. Frisell et al.
European Journal of Neurology, Journal article 2019
Journal article

Cerebrospinal fluid NCAM levels are modulated by disease-modifying therapies
Markus Axelsson, N. Dubuisson, Lenka Novakova, Clas Malmeström, G. Giovannoni et al.
Acta Neurologica Scandinavica, Journal article 2019
Journal article

2018

Plasma neurofilament light chain levels in patients with MS switching from injectable therapies to fingolimod
Fredrik Piehl, Ingrid Kockum, Mohsen Khademi, Kaj Blennow, Jan Lycke et al.
Multiple Sclerosis Journal, Journal article 2018
Journal article

Showing 11 - 20 of 79

Page Manager: Katinka Almrén|Last update: 9/1/2015
Share:

The University of Gothenburg uses cookies to provide you with the best possible user experience. By continuing on this website, you approve of our use of cookies.  What are cookies?